
EyeGate Pharmaceuticals, Inc. Revenue 2011-2026 | EYEG
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue EyeGate Pharmaceuticals, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 12.1 K | 2.69 M | 1.65 M | 408 K | 669 K | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.69 M | 12.1 K | 1.09 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
238 M | - | 2.43 % | $ 254 M | ||
|
Aeterna Zentaris
AEZS
|
9.59 M | - | 5.93 % | $ 314 M | ||
|
Adagene
ADAG
|
10.2 M | $ 1.9 | -3.11 % | $ 107 M | ||
|
Acorda Therapeutics
ACOR
|
118 M | - | -24.86 % | $ 820 K | ||
|
AgeX Therapeutics
AGE
|
142 K | - | -10.17 % | $ 12.2 K | ||
|
Aytu BioScience
AYTU
|
66.4 M | $ 2.71 | 1.88 % | $ 17 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
732 M | $ 25.87 | -0.79 % | $ 1.25 B | ||
|
Alterity Therapeutics Limited
ATHE
|
109 K | $ 3.31 | -4.06 % | $ 7.96 B | ||
|
Aravive
ARAV
|
9.14 M | - | -13.39 % | $ 1.45 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
6.07 B | - | - | $ 40.3 B | ||
|
Aeglea BioTherapeutics
AGLE
|
886 K | - | - | $ 1.01 B | ||
|
Midatech Pharma plc
MTP
|
381 K | - | -18.52 % | $ 27.3 M | ||
|
Brickell Biotech
BBI
|
8.01 M | - | -5.38 % | $ 6.06 M | ||
|
BioLineRx Ltd.
BLRX
|
28.9 M | $ 2.97 | 3.12 % | $ 908 M | ||
|
BeiGene, Ltd.
BGNE
|
3.81 B | - | 0.49 % | $ 251 B | ||
|
Институт стволовых клеток человека
ISKJ
|
1.08 B | - | - | - | ||
|
Ascendis Pharma A/S
ASND
|
364 M | $ 215.29 | 4.59 % | $ 5 B | ||
|
BioNTech SE
BNTX
|
482 M | $ 105.97 | -2.78 % | $ 27.2 B | ||
|
Bellicum Pharmaceuticals
BLCM
|
1.5 M | - | -9.72 % | $ 5.89 M | ||
|
Bio-Path Holdings
BPTH
|
37 K | - | - | $ 100 K | ||
|
Acasti Pharma
ACST
|
100 M | - | 4.01 % | $ 150 M | ||
|
Baudax Bio
BXRX
|
1.27 M | - | 0.59 % | $ 63 K | ||
|
Arrowhead Pharmaceuticals
ARWR
|
829 M | $ 64.74 | 1.41 % | $ 8.66 B | ||
|
Can-Fite BioPharma Ltd.
CANF
|
853 K | $ 3.96 | -1.0 % | $ 8.62 B | ||
|
Burford Capital Limited
BUR
|
330 M | $ 9.63 | -0.93 % | $ 1.56 B | ||
|
CASI Pharmaceuticals
CASI
|
30.2 M | $ 0.95 | -0.72 % | $ 129 M | ||
|
Ayala Pharmaceuticals
AYLA
|
692 K | - | - | $ 7.46 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
60.3 M | - | -15.15 % | $ 60.3 M | ||
|
Celldex Therapeutics
CLDX
|
7.02 M | $ 25.15 | -1.95 % | $ 1.62 M | ||
|
AIkido Pharma
AIKI
|
18.1 M | - | 1.93 % | $ 17.4 M | ||
|
Albireo Pharma
ALBO
|
40.6 M | - | -0.23 % | $ 916 M | ||
|
CureVac N.V.
CVAC
|
48.9 M | - | - | $ 867 M | ||
|
Acer Therapeutics
ACER
|
1.26 M | - | 2.71 % | $ 14 M | ||
|
Alpine Immune Sciences
ALPN
|
30.1 M | - | - | $ 2.17 B | ||
|
AlloVir
ALVR
|
165 K | - | 4.14 % | $ 49.1 M | ||
|
Catalyst Biosciences
CBIO
|
113 M | $ 14.01 | 3.7 % | $ 922 M | ||
|
Ampio Pharmaceuticals
AMPE
|
1.16 M | - | -11.43 % | $ 502 K | ||
|
Biogen
BIIB
|
9.68 B | $ 164.87 | 0.27 % | $ 24 B | ||
|
Avid Bioservices
CDMO
|
140 M | - | - | $ 789 M | ||
|
Catalyst Pharmaceuticals
CPRX
|
492 M | $ 23.32 | 2.71 % | $ 2.76 B | ||
|
Calithera Biosciences
CALA
|
9.75 M | - | -10.95 % | $ 876 K |